662 related articles for article (PubMed ID: 8381804)
1. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.
Imperato-McGinley J; Gautier T; Cai LQ; Yee B; Epstein J; Pochi P
J Clin Endocrinol Metab; 1993 Feb; 76(2):524-8. PubMed ID: 8381804
[TBL] [Abstract][Full Text] [Related]
2. C19 and C21 5 beta/5 alpha metabolite ratios in subjects treated with the 5 alpha-reductase inhibitor finasteride: comparison of male pseudohermaphrodites with inherited 5 alpha-reductase deficiency.
Imperato-McGinley J; Shackleton C; Orlic S; Stoner E
J Clin Endocrinol Metab; 1990 Mar; 70(3):777-82. PubMed ID: 1689740
[TBL] [Abstract][Full Text] [Related]
3. 5 alpha-metabolism in finasteride-treated subjects and male pseudohermaphrodites with inherited 5 alpha-reductase deficiency. A review.
Imperato-McGinley J
Eur Urol; 1991; 20 Suppl 1():78-81. PubMed ID: 1722167
[TBL] [Abstract][Full Text] [Related]
4. MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.
Schwartz JI; Tanaka WK; Wang DZ; Ebel DL; Geissler LA; Dallob A; Hafkin B; Gertz BJ
J Clin Endocrinol Metab; 1997 May; 82(5):1373-7. PubMed ID: 9141518
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose-response studies.
Imperato-McGinley J; Sanchez RS; Spencer JR; Yee B; Vaughan ED
Endocrinology; 1992 Sep; 131(3):1149-56. PubMed ID: 1324152
[TBL] [Abstract][Full Text] [Related]
6. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
7. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
8. The effect of a 5 alpha-reductase inhibitor on androgen physiology in the immature male rat.
George FW; Johnson L; Wilson JD
Endocrinology; 1989 Nov; 125(5):2434-8. PubMed ID: 2551651
[TBL] [Abstract][Full Text] [Related]
9. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
Geller J
J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
[TBL] [Abstract][Full Text] [Related]
10. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
11. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
Bartsch G; Rittmaster RS; Klocker H
Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
[TBL] [Abstract][Full Text] [Related]
12. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract.
George FW
Endocrinology; 1997 Mar; 138(3):871-7. PubMed ID: 9048585
[TBL] [Abstract][Full Text] [Related]
13. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition.
Rhodes L; Primka RL; Berman C; Vergult G; Gabriel M; Pierre-Malice M; Gibelin B
Prostate; 1993; 22(1):43-51. PubMed ID: 8381228
[TBL] [Abstract][Full Text] [Related]
14. Dihydrotestosterone regulation of semen in male pseudohermaphrodites with 5 alpha-reductase-2 deficiency.
Cai LQ; Fratianni CM; Gautier T; Imperato-McGinley J
J Clin Endocrinol Metab; 1994 Aug; 79(2):409-14. PubMed ID: 8045956
[TBL] [Abstract][Full Text] [Related]
15. The clinical development of a 5 alpha-reductase inhibitor, finasteride.
Stoner E
J Steroid Biochem Mol Biol; 1990 Nov; 37(3):375-8. PubMed ID: 1701660
[TBL] [Abstract][Full Text] [Related]
16. Castration-like effects on the human prostate of a 5 alpha-reductase inhibitor, finasteride.
Geller J; Sionit L
J Cell Biochem Suppl; 1992; 16H():109-12. PubMed ID: 1283893
[TBL] [Abstract][Full Text] [Related]
17. Hair growth effects of oral administration of finasteride, a steroid 5 alpha-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque.
Diani AR; Mulholland MJ; Shull KL; Kubicek MF; Johnson GA; Schostarez HJ; Brunden MN; Buhl AE
J Clin Endocrinol Metab; 1992 Feb; 74(2):345-50. PubMed ID: 1309834
[TBL] [Abstract][Full Text] [Related]
18. Effect of MK-906, a specific 5 alpha-reductase inhibitor, on serum androgens and androgen conjugates in normal men.
Rittmaster RS; Stoner E; Thompson DL; Nance D; Lasseter KC
J Androl; 1989; 10(4):259-62. PubMed ID: 2550402
[TBL] [Abstract][Full Text] [Related]
19. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
Stanczyk FZ; Azen CG; Pike MC
J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
[TBL] [Abstract][Full Text] [Related]
20. LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.
Hirsch KS; Jones CD; Audia JE; Andersson S; McQuaid L; Stamm NB; Neubauer BL; Pennington P; Toomey RE; Russell DW
Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5277-81. PubMed ID: 8389478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
